Júlio Oliveira

1.7k total citations
41 papers, 1.1k citations indexed

About

Júlio Oliveira is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Júlio Oliveira has authored 41 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 12 papers in Surgery. Recurrent topics in Júlio Oliveira's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Genomics and Diagnostics (10 papers) and Gastric Cancer Management and Outcomes (7 papers). Júlio Oliveira is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Genomics and Diagnostics (10 papers) and Gastric Cancer Management and Outcomes (7 papers). Júlio Oliveira collaborates with scholars based in Portugal, France and Italy. Júlio Oliveira's co-authors include E. Van Cutsem, David Cunningham, Bengt Glimelius, Christopher Jackson, Eric Van Cutsem, Lúcio Lara Santos, Eurico Monteiro, Juliana M. B. Santos, M. Stahl and Marta Soares and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Júlio Oliveira

37 papers receiving 1.0k citations

Peers

Júlio Oliveira

ONCOL

PRM

SURGE

Kateřina Kubáčková Czechia

Andrea Marchetti Italy

Javier Puente Spain

Janja Ocvirk Slovenia

Matteo Rosellini Italy

Rosario García‐Campelo Spain

Mireia Margelí Vila Spain

Hao‐Wen Sim Australia

Carolyn K. McCourt United States

José María Viéitez Spain

Kateřina Kubáčková Czechia

Júlio Oliveira

429 ×0.9

ONCOL

309 ×0.8

PRM

329 ×1.2

115 ×0.5

SURGE

255 ×1.2

Citations per year, relative to Júlio Oliveira Júlio Oliveira (= 1×) peers Kateřina Kubáčková

Countries citing papers authored by Júlio Oliveira

Since Specialization

Citations

This map shows the geographic impact of Júlio Oliveira's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Júlio Oliveira with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Júlio Oliveira more than expected).

Fields of papers citing papers by Júlio Oliveira

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Júlio Oliveira. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Júlio Oliveira. The network helps show where Júlio Oliveira may publish in the future.

Co-authorship network of co-authors of Júlio Oliveira

This figure shows the co-authorship network connecting the top 25 collaborators of Júlio Oliveira. A scholar is included among the top collaborators of Júlio Oliveira based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Júlio Oliveira. Júlio Oliveira is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tagliamento, Marco, Marie Morfouace, Júlio Oliveira, et al.. (2024). EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers. npj Precision Oncology. 8(1). 37–37. 6 indexed citations

Assis, Joana, et al.. (2024). Pioneering the implementation of a precision oncology strategy in Portugal: the Precision Oncology Platform trial. Acta Oncologica. 63. 482–486.

Voss, Martin H., Benjamin Garmezy, J.P. Maroto Rey, et al.. (2023). 1883MO MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC). Annals of Oncology. 34. S1012–S1012. 7 indexed citations

Morfouace, Marie, Daniel Schulz, Nils Eling, et al.. (2023). 2266P IMMUcan consortium: Focus on the first results of the non-small cell lung cancer (NSCLC) cohort. Annals of Oncology. 34. S1164–S1164. 2 indexed citations

Gelderblom, Hans, Anders Edsjö, Ulrik Lassen, et al.. (2023). 1711P The DRUP-like clinical trials family: A distributed European trial network for equitable access to precision medicine. Annals of Oncology. 34. S933–S934. 1 indexed citations

Pérol, M., Nick Pavlakis, E. Levchenko, et al.. (2019). Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lung Cancer. 138. 79–87. 27 indexed citations

Nunes, Sandra P., Catarina Moreira-Barbosa, Sofia Salta, et al.. (2018). Cell-Free DNA Methylation of Selected Genes Allows for Early Detection of the Major Cancers in Women. Cancers. 10(10). 357–357. 57 indexed citations

Pérol, M., Solange Peters, Nick Pavlakis, et al.. (2018). 138PD_PR Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC). Journal of Thoracic Oncology. 13(4). S80–S81. 1 indexed citations

Guerreiro, I., Ana Rodrigues, Cristina Oliveira, et al.. (2017). P3.02b-088 TKI as First Line Treatment in Advanced Non-Small-Cell Lung Cancer with EGFR Mutations. Journal of Thoracic Oncology. 12(1). S1244–S1245.

10.

Azevedo, Sérgio Jobim, Joana Cunha, Cristina Oliveira, et al.. (2017). P3.02a-028 Anaplastic Lymphoma Kinase Fusion Oncogene Positive Non-Small Cell Lung Cancer - The Experience of an Institution. Journal of Thoracic Oncology. 12(1). S1179–S1179. 1 indexed citations

11.

Bowen, Debra L., Jorge Camarero, Pierre Démolis, et al.. (2015). Early market access of cancer drugs in the EU. Annals of Oncology. 27(1). 96–105. 61 indexed citations

12.

Mello, Ramon Andrade de, F.M. Andrade Pires, Júlio Oliveira, et al.. (2012). EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study. Tumor Biology. 33(6). 2061–2068. 23 indexed citations

13.

Cutsem, E. Van & Júlio Oliveira. (2009). Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology. 20. iv61–iv63. 154 indexed citations

14.

Cutsem, Eric Van & Júlio Oliveira. (2009). Primary colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up. Annals of Oncology. 20. iv49–iv50. 59 indexed citations

15.

Stahl, M. & Júlio Oliveira. (2009). Esophageal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology. 20. iv32–iv33. 28 indexed citations

16.

Vasen, Hans F. A., Andrea E. van der Meulen‐de Jong, Wouter H. de Vos tot Nederveen Cappel, & Júlio Oliveira. (2009). Familial colorectal cancer risk: ESMO Clinical Recommendations. Annals of Oncology. 20. iv51–iv53. 22 indexed citations

17.

Martins, Sheila Cristina Ouriques, et al.. (2009). Clinical significance of macroscopic completeness of mesorectal resection in rectal cancer. Colorectal Disease. 13(4). 381–386. 31 indexed citations

18.

Stahl, M., Vesa Kataja, & Júlio Oliveira. (2005). ESMO Minimal Clinical Recommendations for diagnosis, treatment and follow-up of esophageal cancer. Annals of Oncology. 16. i26–i27. 4 indexed citations

19.

Cunningham, David, L.M. Jost, Gunta Purkalne, & Júlio Oliveira. (2005). ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer. Annals of Oncology. 16. i22–i23. 34 indexed citations

20.

Medeiros, Rui, et al.. (2002). The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. Journal of Human Genetics. 47(8). 413–418. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact